Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Enzon's PEG-Intron A advances to phase III trials for malignant melanoma

Sep. 24, 1998

Procyon receives Japanese patent for prostate cancer treatment

Sep. 24, 1998

Theratope cancer vaccine study fulfills enrollment

Sep. 23, 1998

Immune Response treats first patient in phase Ib colon cancer trial

Sep. 23, 1998

Endorex receives Japanese patent for ImmTher

Sep. 23, 1998

Cell Genesys announces positive phase I/II results using GVAX vaccine for prostate cancer

Sep. 22, 1998

IL-4(38-37)-PE38KDEL treatment results in complete regression of human glioblastoma tumors

Sep. 21, 1998

York Medical's DiaCIM will be administered to cancer patients

Sep. 18, 1998

Techniclone submits phase II TNT protocol to FDA

Sep. 18, 1998

Maxim enters collaborative agreement with BioNative

Sep. 15, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.